Evidence map›Paper›PMID 42663383›Full record

ReviewClinical pharmacology and therapeutics2026

Long-Acting Therapeutics in Pediatric Health: Bridging Innovation and Access.

Prajith Venkatasubramanian, Moherndran Archary, Daniel B Hawcutt, Rachel Daley, Edmund Capparelli, Adeniyi Olagunju

Abstract readReview
In one paragraph

Review in Clinical pharmacology and therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Prajith VenkatasubramanianCentre of Excellence for Long-acting Therapeutics, University of Liverpool, Liverpool, UK.ORCID https://orcid.org/0009-0005-6867-9413
Moherndran ArcharyDepartment of Pediatrics and Child Health, African Health Research Institute, University of KwaZulu-Natal, Victoria Mxenge Hospital, Durban, South Africa.ORCID https://orcid.org/0000-0003-3082-9234
Daniel B HawcuttAlder Hey Research Division and NIHR Alder Hey Clinical Research Facility, Alder Hey Children's NHS Foundation Trust, Liverpool, UK.ORCID https://orcid.org/0000-0002-8120-6507
Rachel DaleyCentre of Excellence for Long-acting Therapeutics, University of Liverpool, Liverpool, UK.ORCID https://orcid.org/0009-0003-8884-2658
Edmund CapparelliSkaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, California, USA.ORCID https://orcid.org/0000-0002-1630-0505
Adeniyi OlagunjuCentre of Excellence for Long-acting Therapeutics, University of Liverpool, Liverpool, UK.ORCID https://orcid.org/0000-0002-6588-5749

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Children have distinct therapeutic needs arising from age-dependent physiology, disease epidemiology, formulation requirements, dosing considerations, and safety vulnerabilities. Despite substantial reductions in childhood mortality over the past three decades, nearly 5 million children under five died in 2023, with infectious diseases continuing to contribute substantially to preventable morbidity and mortality. Long-acting therapeutics (LATs) may help address selected pediatric health priorities by sustaining therapeutic or prophylactic exposure, reducing dosing frequency, and improving adherence and implementation feasibility. This review synthesizes insights from the pediatric health session of the Community of Practice for Long-acting Therapeutics for Maternal and Paediatric Health workshop. The session considered priority pediatric conditions in which existing or emerging LAT approaches could have clinical or public health impact, including lower respiratory tract infections, malaria, tuberculosis, HIV, and syphilis, as well as selected noninfectious indications such as childhood cancer and growth hormone deficiency. We then examine clinical pharmacology and safety considerations central to pediatric LAT development, including developmental pharmacokinetics, absorption-limited disposition and flip-flop kinetics, pharmacokinetic tailing, dose selection, model-informed development, and injection-site tolerability. The review also discusses long-acting technology platforms with potential pediatric applications, route-of-administration considerations, excipient safety, formulation design, acceptability, and implementation challenges. Finally, we propose recommendations to support pediatric LAT development, including early integration of developmental pharmacology, age- and weight-informed dosing, standardized acceptability assessment, product-attribute frameworks, regulatory engagement, and equitable access planning. Realizing the potential of LATs for children will require coordinated, child-centered, and equity-driven approaches that address evidence generation, formulation suitability, implementation context, and affordability from the outset.

Identifiers

PMID42663383
PMCPMC13523535

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.